In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...